Crescent Biopharma director granted 11,050 options

CRESCENT BIOPHARMA, INC. director Alexandra Balcom received a grant of stock options covering 11,050 ordinary shares.

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. director Alexandra Balcom received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036.

The grant vests in full on the earlier of June 2, 2027 or the date of the company’s next annual meeting of shareholders, as long as she continues serving the company. Following this grant, she holds options on 11,050 shares directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.

Insider Trade Summary

Grant/Award: 11,050 shares

Grant/Award 1 txn

Insider Balcom Alexandra

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	11,050	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 11,050 contracts (Direct)

Footnotes (1)

1. F1. This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options granted: 11,050 options Exercise price: $17.01 per share Shares underlying options: 11,050 ordinary shares +2 more

5 metrics

Options granted 11,050 options Stock Option (Right to Buy) grant to director

Exercise price $17.01 per share Conversion or exercise price of options

Shares underlying options 11,050 ordinary shares Underlying security for the option grant

Expiration date June 2, 2036 Option expiration for the grant

Holdings after grant 11,050 options Total derivative shares following transaction

Key Terms

Stock Option (Right to Buy), ordinary shares, vests in full, annual meeting of shareholders, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

ordinary shares financial

"right to purchase 11,050 of the Issuer's ordinary shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vests in full financial

"and vests in full on the earlier of (i) June 2, 2027"

annual meeting of shareholders financial

"or (ii) the date of the Issuer's next annual meeting of shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

continued service financial

"in each case, subject to the Reporting Person's continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Crescent Biopharma (CBIO) director Alexandra Balcom report on this Form 4?

She reported receiving a grant of stock options for 11,050 ordinary shares. These options are compensation, not an open-market trade, and give her the right to buy shares at a fixed exercise price if vesting conditions are met over time.

How many Crescent Biopharma (CBIO) shares are covered by Alexandra Balcom’s new options?

The grant covers options on 11,050 ordinary shares of Crescent Biopharma. Each option represents the right to purchase one share at a preset price if and when the option vests and is exercised in the future under its terms.

What is the exercise price and expiration date of Alexandra Balcom’s CBIO stock options?

The options have an exercise price of $17.01 per share and expire on June 2, 2036. This means she can choose to buy shares at $17.01 anytime after vesting up to the stated expiration date.

When do Alexandra Balcom’s Crescent Biopharma (CBIO) options vest?

The options vest in full on the earlier of June 2, 2027, or the date of Crescent Biopharma’s next annual shareholder meeting. Vesting is conditioned on her continued service to the company through that date, aligning compensation with ongoing board involvement.

Is Alexandra Balcom’s CBIO Form 4 a stock purchase or a compensation grant?

It is a compensation grant of stock options, not an open-market stock purchase. The filing uses transaction code “A” for a grant or award, reflecting equity-based pay that may become valuable if the share price exceeds the $17.01 exercise level.

How many CBIO options does Alexandra Balcom hold after this transaction?

After this transaction, she holds options to acquire 11,050 Crescent Biopharma ordinary shares. This entire position comes from the newly granted award, providing potential future ownership if the options vest and she decides to exercise them before expiration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/03/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Balcom Alexandra

(Last) (First) (Middle)

C/O/ CRESCENT BIOPHARMA, INC.

300 FIFTH AVENUE

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRESCENT BIOPHARMA, INC. [ CBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$17.01	06/02/2026		A		11,050		(1)	06/02/2036	Ordinary Shares	11,050	$0	11,050	D

Explanation of Responses:

1. This option represents a right to purchase 11,050 of the Issuer's ordinary shares and vests in full on the earlier of (i) June 2, 2027 or (ii) the date of the Issuer's next annual meeting of shareholders, in each case, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Barbara Bispham, as attorney-in-fact for Alexandra Balcom	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)